financetom
Business
financetom
/
Business
/
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial
Jun 26, 2024 8:27 AM

11:13 AM EDT, 06/26/2024 (MT Newswires) -- Novo Nordisk A/S ( NVO ) said Wednesday it will recognize an impairment loss of around 5.7 billion Danish Krone ($816.2 million) in Q2 after its Clarion-CKD phase 3 trial failed to meet its primary endpoint.

Price: 144.19, Change: -2.72, Percent Change: -1.85

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved